These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 25584808

  • 1. Identification of miRNAs that modulate glucocerebrosidase activity in Gaucher disease cells.
    Siebert M, Westbroek W, Chen YC, Moaven N, Li Y, Velayati A, Saraiva-Pereira ML, Martin SE, Sidransky E.
    RNA Biol; 2014; 11(10):1291-300. PubMed ID: 25584808
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase.
    Reczek D, Schwake M, Schröder J, Hughes H, Blanz J, Jin X, Brondyk W, Van Patten S, Edmunds T, Saftig P.
    Cell; 2007 Nov 16; 131(4):770-83. PubMed ID: 18022370
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Activation and Purification of ß-Glucocerebrosidase by Exploiting its Transporter LIMP-2 - Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease.
    Dobert JP, Bub S, Mächtel R, Januliene D, Steger L, Regensburger M, Wilfling S, Chen JX, Dejung M, Plötz S, Hehr U, Moeller A, Arnold P, Zunke F.
    Adv Sci (Weinh); 2024 Jul 16; 11(25):e2401641. PubMed ID: 38666485
    [Abstract] [Full Text] [Related]

  • 6. Validation of anti-glucocerebrosidase antibodies for western blot analysis on protein lysates of murine and human cells.
    Qi W, Davidson BA, Nguyen M, Lindstrom T, Grey RJ, Burnett R, Aflaki E, Sidransky E, Westbroek W.
    Biochem J; 2019 Jan 25; 476(2):261-274. PubMed ID: 30578288
    [Abstract] [Full Text] [Related]

  • 7. Localization of active endogenous and exogenous β-glucocerebrosidase by correlative light-electron microscopy in human fibroblasts.
    van Meel E, Bos E, van der Lienden MJC, Overkleeft HS, van Kasteren SI, Koster AJ, Aerts JMFG.
    Traffic; 2019 May 25; 20(5):346-356. PubMed ID: 30895685
    [Abstract] [Full Text] [Related]

  • 8. Lysosomal integral membrane protein-2: a new player in lysosome-related pathology.
    Gonzalez A, Valeiras M, Sidransky E, Tayebi N.
    Mol Genet Metab; 2014 Feb 25; 111(2):84-91. PubMed ID: 24389070
    [Abstract] [Full Text] [Related]

  • 9. Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease.
    Serra-Vinardell J, Díaz L, Gutiérrez-de Terán H, Sánchez-Ollé G, Bujons J, Michelakakis H, Mavridou I, Aerts JM, Delgado A, Grinberg D, Vilageliu L, Casas J.
    Int J Biochem Cell Biol; 2014 Sep 25; 54():245-54. PubMed ID: 25084554
    [Abstract] [Full Text] [Related]

  • 10. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
    Ambrosi G, Ghezzi C, Zangaglia R, Levandis G, Pacchetti C, Blandini F.
    Neurobiol Dis; 2015 Oct 25; 82():235-242. PubMed ID: 26094596
    [Abstract] [Full Text] [Related]

  • 11. The LIMP-2/SCARB2 binding motif on acid β-glucosidase: basic and applied implications for Gaucher disease and associated neurodegenerative diseases.
    Liou B, Haffey WD, Greis KD, Grabowski GA.
    J Biol Chem; 2014 Oct 24; 289(43):30063-74. PubMed ID: 25202012
    [Abstract] [Full Text] [Related]

  • 12. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, Foltynie T, Cooper JM, Abramov AY, Gegg M, Schapira AH.
    Brain; 2014 May 24; 137(Pt 5):1481-95. PubMed ID: 24574503
    [Abstract] [Full Text] [Related]

  • 13. Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts.
    Van Weely S, Van Leeuwen MB, Jansen ID, De Bruijn MA, Brouwer-Kelder EM, Schram AW, Sa Miranda MC, Barranger JA, Petersen EM, Goldblatt J.
    Biochim Biophys Acta; 1991 Jun 05; 1096(4):301-11. PubMed ID: 1829642
    [Abstract] [Full Text] [Related]

  • 14. Retrovirus-mediated transfer of the human glucocerebrosidase gene to Gaucher fibroblasts.
    Choudary PV, Barranger JA, Tsuji S, Mayor J, LaMarca ME, Cepko CL, Mulligan RC, Ginns EI.
    Mol Biol Med; 1986 Jun 05; 3(3):293-9. PubMed ID: 3736391
    [Abstract] [Full Text] [Related]

  • 15. Viral delivery of a microRNA to Gba to the mouse central nervous system models neuronopathic Gaucher disease.
    Jackson KL, Viel C, Clarke J, Bu J, Chan M, Wang B, Shihabuddin LS, Sardi SP.
    Neurobiol Dis; 2019 Oct 05; 130():104513. PubMed ID: 31233883
    [Abstract] [Full Text] [Related]

  • 16. A mutation in SCARB2 is a modifier in Gaucher disease.
    Velayati A, DePaolo J, Gupta N, Choi JH, Moaven N, Westbroek W, Goker-Alpan O, Goldin E, Stubblefield BK, Kolodny E, Tayebi N, Sidransky E.
    Hum Mutat; 2011 Nov 05; 32(11):1232-8. PubMed ID: 21796727
    [Abstract] [Full Text] [Related]

  • 17. Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.
    van Weely S, van den Berg M, Barranger JA, Sa Miranda MC, Tager JM, Aerts JM.
    J Clin Invest; 1993 Mar 05; 91(3):1167-75. PubMed ID: 8450045
    [Abstract] [Full Text] [Related]

  • 18. Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-glucocerebrosidase.
    Blanz J, Groth J, Zachos C, Wehling C, Saftig P, Schwake M.
    Hum Mol Genet; 2010 Feb 15; 19(4):563-72. PubMed ID: 19933215
    [Abstract] [Full Text] [Related]

  • 19. High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson's disease.
    Williams D, Glasstetter LM, Jong TT, Chen T, Kapoor A, Zhu S, Zhu Y, Calvo R, Gehrlein A, Wong K, Hogan AN, Vocadlo DJ, Jagasia R, Marugan JJ, Sidransky E, Henderson MJ, Chen Y.
    Proc Natl Acad Sci U S A; 2024 Oct 15; 121(42):e2406009121. PubMed ID: 39388267
    [Abstract] [Full Text] [Related]

  • 20. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity.
    Ron I, Horowitz M.
    Hum Mol Genet; 2005 Aug 15; 14(16):2387-98. PubMed ID: 16000318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.